SOLICITATION NOTICE
B -- SPECIAL STUDIES AND ANALYSIS, ANALYSIS OF PROSTATE CANCER DATA
- Notice Date
- 6/29/2004
- Notice Type
- Solicitation Notice
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, Center for Disease Control and Prevention, Acquisition and Assistance Field Branch (Pittsburgh), Post Office Box 18070 Cochrans Mill Road, Pittsburgh, PA, 15236-0070
- ZIP Code
- 15236-0070
- Solicitation Number
- MLM000HCL84-2004-10249
- Response Due
- 7/13/2004
- Archive Date
- 7/28/2004
- Point of Contact
- Margaret Mooney, Purchasing Agent, Phone (412)386-6431, Fax (412)386-6843, - John Columbia, Contract Specialist, Phone 412-386-4458, Fax 412-386-6429,
- E-Mail Address
-
zia3@cdc.gov, akq8@cdc.gov
- Description
- The Centers for Disease Control and Prevention (CDC) intends to negotiate on a sole source basis with Kaiser Permanente Northwest (Kaiser NW) under the authority of FAR 6.302-1 to perform analyses of data on subjects who were included in a case-control study of PSA and DRE screening in relation to prostate cancer mortality. These analyses will include: 1) risk factors for prostate cancer mortality; 2) factors associated with prostate cancer testing by PSA and DRE; and 3) race and prostate cancer treatment. Kaiser NW is the only known contractor with access to the required data sets consisting of medical records of 608 Caucasian men and 161 African-American men who died of prostate cancer from 1997 ? 2001 and a comparison group of 929 controls, matched to cases on age, race, length of health plan membership, and specific health plan. Since these analyses are a progression from previous work completed, it is critical that the exact set of samples be used and analyzed in the same manner. This acquisition is being processed under FAR Part 13, Simplified Acquisition Procedures. I. BACKGROUND Prostate cancer has few known risk factors. Only age, race, and family history of prostate cancer have been consistently associated with prostate cancer incidence. Although only a small proportion of prostate cancers are aggressive enough to lead to death, there have been few studies of the relationship between potential risk factors and prostate cancer mortality. In addition, few studies have had enough African-American subjects to stratify risk factor analyses on race. Little is known about the factors that are associated with use of prostate cancer screening tests, particularly for prostate-specific antigen (PSA) testing. Questions on PSA testing have only recently been added to national surveys. Survey data on PSA and digital rectal exam (DRE) testing may also be of limited value since patients may not know whether they have had these tests. Controversy surrounds the different screening and treatment modalities for prostate cancer. Prior studies have demonstrated variations in treatment by race, with African-Americans receiving less aggressive treatment than Caucasians, even after taking into account stage, grade and age at diagnosis. Hypotheses advanced for receipt of less aggressive treatment by African-Americans include more aggressive tumors, poorer health status, inability to afford medical treatment, personal decision to refuse aggressive treatment, and provider racism, among others. Since African-Americans are at higher risk of prostate cancer than men of other races, this issue deserves further study. In a recent case-control study of PSA and DRE screening in relation to prostate cancer mortality, information was collected from the medical records of 608 Caucasian men and 161 African-American men who died of prostate cancer from 1997 to 2001 and a comparison group of 929 controls, matched to the cases on age, race, length of health plan membership, and health plan (Kaiser Permanente Northern California, Kaiser Permanente Southern California, Kaiser Permanente Northwest, and Henry Ford Health System). The primary purpose of the case-control study was to examine whether screening with the PSA test or DRE was associated with reduced prostate cancer mortality. However, data from the study may also be used for additional analyses related to prostate cancer. II. PURPOSE The vendor will perform three analyses of data on subjects who were included in the case-control study of PSA and DRE screening and prostate cancer mortality. These analyses would be on the following three topics: (1) risk factors for prostate cancer mortality, (2) factors associated with prostate cancer testing by PSA and DRE, and (3) race and prostate cancer treatment. III. SCOPE OF WORK Using the data collected in the case-control study of PSA and DRE screening referenced in Section I. Background, the vendor shall furnish all labor, materials and equipment required to analyze the data in the three topic areas listed above. The vendor shall prepare an analysis plan and a report in the form of a manuscript for each topic area listed above. IV. TASKS TO BE PERFORMED The vendor shall perform the following tasks: A.) Perform an analysis of risk factors for prostate cancer mortality. This analysis will examine the association of several demographic, health and behavioral factors with prostate cancer mortality, using data collected as part of the case-control study of prostate cancer screening and mortality. The analysis will also investigate differences by race in the relationship between potential risk factors and prostate cancer mortality. Factors to be examined will include age, race, height and weight, occupation and industry, history of tobacco use, personal and family history of cancer, history of hypertension and use of antihypertensive medications, history of diabetes and use of diabetic medications, history of vasectomy, and history of several urological conditions or procedures, including benign prostatic hypertrophy (BPH), prostatitis, and transurethral prostatectomy (TURP). B.) Prepare an analysis plan which describes the plan for the analysis of risk factors for prostate cancer mortality (described in Task A) and includes information on the variables to be examined in the analysis, the analysis methods, and draft table shells. C.) Provide a report in the form of a manuscript which describes the background, methods, results and interpretation of the results of the analysis of risk factors for prostate cancer mortality (described in Task A). D.) Perform an analysis of factors associated with prostate cancer testing by PSA and DRE. This analysis will examine demographic, health, and behavioral factors associated with prostate cancer screening and with prostate cancer testing that is not screening, by race (Caucasian or African-American) and type of test (PSA or DRE). This analysis will be conducted among control subjects from the case-control study of prostate cancer screening and mortality. For subjects who were age 65 and over, the study datasets may be linked to Health Status Questionnaires filled out by health plan members when they become eligible for Medicare. E.) Prepare an analysis plan which describes the plan for the analysis of factors associated with prostate cancer testing by PSA and DRE (described in Task D) and includes information on the variables to be examined in the analysis, the analysis methods, and draft table shells. F.) Provide a report in the form of a manuscript which describes the background, methods, results and interpretation of the results of the analysis of factors associated with prostate cancer testing by PSA and DRE (described in Task D). G.) Perform an analysis of race and prostate cancer treatment. This analysis will examine differences in the treatment of prostate cancer by race in the case subjects (fatal prostate cancer cases) who were included in the case-control study of prostate cancer screening and mortality. The relationship between treatment type and demographic, health and behavioral factors will be examined in this population. The analysis will investigate whether these other factors might explain the differences in treatment by race. Demographic and health information that was collected as part of the case-control study will be used in this analysis. Pharmacy data that were collected will be used to generate a comorbidity index. H.) Prepare an analysis plan which describes the plan for the analysis of race and prostate cancer treatment (described in Task G) and includes information on the variables to be examined in the analysis, the analysis methods, and draft table shells. I.) Provide a report in the form of a manuscript which describes the background, methods, results and interpretation of the results of the analysis of race and prostate cancer treatment (described in Task G). This report should discuss the limitations of including only fatal prostate cancer cases in the analysis. V. MINIMUM VENDOR QUALIFICATIONS A. Experience in analysis of case-control study data on prostate cancer screening. B. Knowledge of prostate cancer screening tests (PSA and DRE). C. Access to medical records from case-control study of PSA and DRE screening in relation to prostate cancer mortality, information, which included the medical records of 608 Caucasian men and 161 African-American men who died of prostate cancer from 1997 to 2001 and a comparison group of 929 controls, matched to the cases on age, race, length of health plan membership, and health plan (Kaiser Permanente Northern California, Kaiser Permanente Southern California, Kaiser Permanente Northwest, and Henry Ford Health System). CDC needs the vendor to perform three analyses of data on subjects who were included in the case-control study of PSA and DRE screening and prostate cancer mortality. These analyses would be on the following three topics: (1) risk factors for prostate cancer mortality, (2) factors associated with prostate cancer testing by PSA and DRE, and (3) race and prostate cancer treatment. VI. MINIMUM REQUIREMENTS FOR VENDOR AND WHY THESE MINIMUM REQUIREMENTS ARE NECESSARY TO FULFILL THE CDC NEED In order to prepare the deliverables that are required for this purchase order, the vendor must have experience in the analysis of case-control study data on prostate cancer screening. The vendor must also have knowledge of prostate cancer screening tests (PSA and DRE). In order to conduct the analyses that are required for this purchase order, the vendor must have access to data on 608 Caucasian men and 161 African-American men who died of prostate cancer from 1997 to 2001 and a comparison group of 929 controls, from a case-control study of PSA and DRE screening in relation to prostate cancer mortality. The vendor must also have access to data from Health Status Questionnaires filled out by Kaiser health plan members when they become eligible for Medicare. The case-control study data and the Health Status Questionnaire data for all men included in the case-control study are located at Kaiser Permanente Northwest. Kaiser Permanente Northwest is the only vendor who can access and use these data because they have the data in-house. Through this announcement, alternate sources are being offered the opportunity to demonstrate their capabilities to provide the services specifically identified above. To be considered qualified, sources must submit a capabilities statement which demonstrates in writing that they possess at least 2 years of experience in delivering the kind of activities outlined in the SOW. Responses must contain no more then 10 pages total. Qualified organizations are encouraged to submit a capabilities statement which addresses the requirements and contains material in sufficient detail to allow CDC to determine if the party can perform this requirement. Capabilities are to be received in the contracting office no later than fifteen (15) days from the date of this announcement. Submit written information to: Margaret Mooney, MS-P05, Reference: MLM000HCL84-2004-10249, CDC/PGO/AAFB, 626 Cochrans Mill Road, PO Box 18070, Pittsburgh, PA 15236-0070 or responses may be submitted electronically to Margaret Mooney at zia3@cdc.gov The intent of this synopsis is to determine whether alternative sources exist. Information will be solely used for the purpose of determining whether to conduct a competitive procurement. A determination by the Government not to compete this proposed requirement based responses to this notice is solely within the discretion of the Government. All responsible sources may submit a response, which shall be considered by the Agency.
- Record
- SN00611831-W 20040701/040629211749 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |